Posted on

Aflibercept [2mg intravitreal injection] for first-line treatment of Wet Age-related Macular Degeneration

General Track – Pre-Cycle 1 | Drugs

Assessment Status

  • Clinical Assessment Complete; For commissioning out – EE and ELSHI Assessment
  • Target Timeline of Release of Preliminary Recommendation – Q4 2025

Relevant Information

  • Topic Assignment: External Assessment Group (EAG)
  • Policy Questions:
    • Should Ranibizumab vs. Aflibercept vs. Dexamethasone for the treatment of  diabetic macular edema  be funded by the Department of Health (DOH) and/or PhilHealth through its inclusion in the Philippine National Formulary (PNF)?
    • Should Ranibizumab vs. Aflibercept vs. Dexamethasone for the treatment of  macular edema secondary to retinal vein occlusion be funded by the DOH and/or PhilHealth through its inclusion in the Philippine National Formulary (PNF)?
    • Should Ranibizumab vs. Aflibercept for the treatment of  wet or neovascular age-related macular degeneration  be funded by the Department of Health (DOH) and/or PhilHealth through its inclusion in the Philippine National Formulary (PNF)?

Evidence and Relevant Documents

Back to Assessments Page